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Abstract 
Background: With modern advances in cardiac care, patients with congenital cyanotic heart disease 
(CCHD) are living longer. As a result of this, the medical community is recognizing an increasing 
prevalence of non-cardiac complications in these patients. One of the most common complications is 
development of cyanotic nephropathy, which in turn leads to polycythemia. Elevated hematocrit levels can 
be an indicator of this process. Due to increased prevalence and a relative lack of qualified specialists, 
primary care clinicians are in need of an alternative, inexpensive test to establish these patients’ risk of 
developing cyanotic nephropathy. Measurement of hematocrit fulfills this need. 
Methods: An exhaustive search of available medical literature was performed using Medline-Ovid, 
CINAHL, and Web of Science, using the search terms heart defects, kidney diseases, and hematocrit. 
Google Scholar was also searched, using the terms congenital cyanotic heart disease, kidney disease, 
and hematocrit. Included studies were evaluated using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) Working Group guidelines. 
Results: A total of 78 studies were screened. The cumulative result of the search gave a total of two 
studies meeting inclusion criteria: two cross-sectional observational studies demonstrating that elevated 
hematocrit levels can be a reliable indicator of risk of progression to cyanotic nephropathy in patients 
with CCHD. 
Conclusion: Elevated hematocrit levels can be a reliable prognostic indicator of the development of 
cyanotic nephropathy in patients with CCHD. Hematocrit evaluation is the best resource available to 
primary care clinicians when evaluating patients with CCHD for the risk of developing cyanotic 
nephropathy. Current evidence suggests that frequent hematocrit screening could lead to early 
identification of renal damage. By using hematocrit as an evaluation tool, primary care clinicians can 
positively impact the quality of life of patients with CCHD. Close monitoring of these patients with 
appropriate diagnostic studies, such as hematocrit, can also lead to a more manageable distribution of 
patients with CCHD among the healthcare system between specialists and primary care providers. 
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Abstract  
Background: With modern advances in cardiac care, patients with congenital 
cyanotic heart disease (CCHD) are living longer. As a result of this, the medical 
community is recognizing an increasing prevalence of non-cardiac complications in 
these patients. One of the most common complications is development of cyanotic 
nephropathy, which in turn leads to polycythemia. Elevated hematocrit levels can be 
an indicator of this process. Due to increased prevalence and a relative lack of 
qualified specialists, primary care clinicians are in need of an alternative, inexpensive 
test to establish these patients’ risk of developing cyanotic nephropathy. 
Measurement of hematocrit fulfills this need. 
Methods:  An exhaustive search of available medical literature was performed 
using Medline-Ovid, CINAHL, and Web of Science, using the search terms heart 
defects, kidney diseases, and hematocrit. Google Scholar was also searched, using 
the terms congenital cyanotic heart disease, kidney disease, and hematocrit. 
Included studies were evaluated using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) Working Group guidelines. 
Results:  A total of 78 studies were screened. The cumulative result of the search 
gave a total of two studies meeting inclusion criteria: two cross-sectional 
observational studies demonstrating that elevated hematocrit levels can be a reliable 
indicator of risk of progression to cyanotic nephropathy in patients with CCHD. 
Conclusion:  Elevated hematocrit levels can be a reliable prognostic indicator of 
the development of cyanotic nephropathy in patients with CCHD. Hematocrit 
evaluation is the best resource available to primary care clinicians when evaluating 
patients with CCHD for the risk of developing cyanotic nephropathy. Current 
evidence suggests that frequent hematocrit screening could lead to early 
identification of renal damage. By using hematocrit as an evaluation tool, primary 
care clinicians can positively impact the quality of life of patients with CCHD. Close 
monitoring of these patients with appropriate diagnostic studies, such as hematocrit, 
can also lead to a more manageable distribution of patients with CCHD among the 
healthcare system between specialists and primary care providers. 
Keywords:  congenital cyanotic heart disease, heart defects, chronic kidney 
disease, cyanotic nephropathy, hematocrit 
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Hematocrit Evaluation for Identifying Risk of 
Cyanotic Nephropathy in Patients with 
Congenital Cyanotic Heart Disease 
BACKGROUND 
 Congenital cyanotic heart disease (CCHD) used to be considered a terminal 
diagnosis given to neonates. However, with modern advances in cardiac care, more 
of these patients are living into adulthood.1 As the life expectancy of patients with 
CCHD continues to grow,1 the medical community is recognizing an increasing 
prevalence of non-cardiac complications in these patients. Among these 
complications are polycythemia and cyanotic nephropathy.2 
 The demographic changes and complications associated with CCHD present 
many obstacles for clinicians to overcome. Current practice is for the primary care 
provider to refer patients with CCHD to a pediatric cardiologist. While all patients 
with CCHD should be under the care of a specialist, this approach could cost the 
patient valuable time waiting for an appointment with an overbooked specialist. Also, 
this does not address the gap in care these patients experience once they become 
adults. Patients with CCHD are at greater risk of non-cardiac complications as they 
age. There are simply not enough adult CCHD specialists available to meet the 
increasing patient demand. This leads to an increased patient burden on primary 
care clinicians. 
These patients often require expensive, labor-intensive, and frequent 
evaluation. Primary care clinicians are in need of an alternative, inexpensive test to 
establish these patients’ risk of acquiring complications. A simple, routine blood test 
fulfills this need. Due to the pathophysiologic effects of CCHD on the kidneys, 
clinicians may be able to use hematocrit levels to earlier detect the development of 
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cyanotic nephropathy.   
 CCHD leads to chronic hypoxemia due to cardiac insufficiency. The kidneys 
respond to this by increasing production of erythropoietin, leading to an increased 
production of red blood cells (RBC). Elevated hematocrit is a reflection of this 
increased number of circulating RBCs, and is an early indication of this process. This 
cascade leads to eventual polycythemia, which results in reduced renal plasma flow 
and filtration.3 This decrease in filtration rate, as well as increased creatinine and 
urate, are classic markers of renal dysfunction. However, these classic indicators of 
nephropathy occur later in the course of the disease process.4 Therefore, elevated 
hematocrit can be a harbinger of cyanotic nephropathy in patients with CCHD. 
Monitoring hematocrit levels can allow for the early detection necessary to prevent 
irreversible kidney damage. 
METHODS 
 An exhaustive search was performed using Medline-Ovid, CINAHL, and Web of 
Science, using the following search terms: heart defects, kidney diseases, and 
hematocrit. Google Scholar was also searched, using the terms congenital cyanotic 
heart disease, kidney disease, and hematocrit. 
 Inclusion criteria were defined as studies that measured hematocrit levels in 
patients with CCHD who developed cyanotic nephropathy. Studies not meeting these 
criteria were excluded, as well as studies that were published greater than 20 years 
ago. Included studies were evaluated using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group guidelines.5  
RESULTS 
 A total of 78 studies were screened. Medline-Ovid yielded nine results, and 
two of them met inclusion criteria. No results were found using CINAHL. Web of 
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Science yielded two results; neither met inclusion criteria. Google Scholar yielded 
5890 results. Seventeen of these results were screened, and one study met inclusion 
criteria; this study was a duplicate that was previously found in the Medline-Ovid 
search. The citations from relevant studies were also searched. The cumulative result 
of the search gave a total of two studies. One additional retrospective analysis was 
found, but was excluded due to a publishing date greater than 20 years old. See 
Table 1.  
Dittrich et al 
Dittrich et al6 is a cross-sectional observational study that evaluated 26 
patients with CCHD. Patients ranged in age from 10 to 42 years old, and were both 
male and female. There was no specification for the male to female ratio of study 
participants. Using random urine specimens, first morning void urine collections, and 
timed urine samples, the following values were obtained: total urine protein, 
transferrin, IgG, albumin, α1-microglobulin, and activity of N-acetyl-β-D-
glucosaminidase. Blood samples were drawn within one hour of the start of urine 
collection and were used to obtain serum creatinine, arterial oxygen saturation, and 
hematocrit values. These values were compared to established norms and used to 
calculate GFR.6 
Of the 26 patients that participated in this study, the median arterial oxygen 
saturation was 80% and the median hematocrit was 52.7%. Ten of these patients had 
elevated urinary albumin/creatinine ratio, indicating renal dysfunction. There was a 
significant relationship (p<0.05) between increased serum hematocrit and urinary protein 
excretion. Hematocrit was the only positive hematologic marker associated with 
albuminuria (p=0.0408) when the group was split between those patients with and 
without albuminuria. When proteinuria and albuminuria were compared to other studied 
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biomarkers, they were found to be the most sensitive parameters of early glomerular 
injury.6 
Awad et al  
Awad et al4 is also a cross-sectional observational study with the objective to 
find useful biomarkers in identifying cyanotic nephropathy in patients with CCHD. A 
total of 86 pediatric patients were studied, 72 of which were patients with CCHD. Of 
the 86 participants, 14 were healthy patients and were used as a control group. The 
treatment group was further separated into 4 equal groups. Group 1 consisted of 18 
patients less than 1 year old. Group 2 also had 18 patients, between 1 and 4 years 
old. Five to 9 year old patients were placed in Group 3, and greater than or equal to 
10 year old patients were placed in Group 4. Groups 3 and 4 also had 18 patients 
each. This study had particular focus on the effect of palliative cardiac surgery, and 
therefore constructed an additional group of 10 patients (ranging in age from 1 year 
to 10 years) who underwent palliative surgery. The male to female ratio was not 
reported.4 
Hematocrit level was obtained using the pin-prick method with microcapillary 
tube centrifugation and oxyhemoglobin saturation was measured via pulse oximetry.4 
For all groups, a random morning urine sample was used to obtain total urine 
protein, α1-microglobulin, leucine-aminopeptidase, N-acetyl-β-D-glucosaminidase, 
and creatinine concentration. However, since these biomarkers are not the focus of 
this review, they will not be discussed here. 
This study also found a significant increase in hematocrit and urinary 
biomarkers in patients with CCHD as compared to the control group. The P values for 
all delineated groups were <0.05 when compared with the control group. By dividing 
the participants into groups according to age, Awad et al4 also found a significant 
correlation between patient age and hematocrit. The percentage of patients with 
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abnormal hematocrit increased from 11 to 83% from the youngest to the oldest age 
groups. In the additional palliative surgery group, Awad et al4 demonstrated a 
significant decrease in hematocrit percentage and increase in oxygen saturation after 
surgery as compared to before. Hematocrit was 51.6%±10.5% before surgery, and 
dropped to 43.7%±76.4% after surgery, and oxygen saturation rose from 
63.9%±5.56% to 92.6%±1.57%.4 
DISCUSSION 
 When considering the risk of patients with CCHD developing cyanotic 
nephropathy, both studies4,6 included in this systematic review point to two 
important predisposing factors: the extent of hematocrit elevation and the duration 
of cyanosis. Both variables appear to play a substantial role in predicting the CCHD 
patient’s risk of developing cyanotic nephropathy. 
Perloff et al7 demonstrated that hematocrit levels were 55% to 75% in CCHD 
patients immediately before death, as compared to the control group with hematocrit 
levels of 34% to 44%. Dittrich et al6 found a statistically significant (p<0.05) 
correlation between elevated hematocrit and urine protein excretion, thus indicating 
renal dysfunction. In fact, when the group was split in half by the median 
hematocrit, the patients with higher hematocrit levels showed statistical differences 
in serum creatinine, urine albumin, and proteinuria.6 
This study6 went a step further and analyzed other hematologic markers, to 
determine whether there were additional correlations with evidence of cyanotic 
nephropathy. RBC count, hemoglobin, mean cell volume (MCV), mean cell 
hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC) were all 
measured, and none were found to have predictive value of renal cyanotic 
nephropathy.6 This implies that by solely looking at hematocrit levels, a clinician can 
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accurately predict the patient’s risk of developing this fatal complication of CCHD. 
Another study3 showed that acute changes in hematocrit are accompanied by 
acute changes in renal perfusion, which is actually reversible. So with early 
identification, this process of kidney damage can be reversed. The implications of 
this are substantial. If an abrupt increase in hematocrit is identified early enough, 
the early stages of renal damage can be treated, and fulminant renal failure can be 
prevented.7 However, the longer cyanotic nephropathy continues, the increasing 
likelihood that the resultant renal failure will become chronic. Patients with CCHD 
could live longer, healthier lives if clinicians would frequently monitor this value. 
The other important risk factor in the development of cyanotic nephropathy, 
is the duration of cyanosis. Duration of cyanosis is directly related to the age of the 
patient.4,6 The longer the CCHD patient is exposed to cyanosis, the greater their risk 
of developing cyanotic nephropathy. This is confirmed by Krull et al8 findings that 
patients with CCHD develop significant proteinuria and renal dysfunction in the 
second decade of life. Although Awad et al4 only studied children, it was still found 
that patients developed abnormal lab levels for glomerular function and tubular 
integrity the longer they were exposed to cyanosis. 
Wilcox et al3 conducted a study on CCHD patients with polycythemia, which 
further correlates the relationship of hematocrit to renal damage. This study 
primarily investigated cor pulmonale as it relates to pulmonary function and CCHD. 
However, it also commented extensively on the observed elevated hematocrit in 
these patients (mean of 62% ± 6% SD).6 
The repeated findings of elevated hematocrit in multiple studies3,4,6,7,9 further 
support the assertion that this measure is a valuable indicator of progression to 
cyanotic nephropathy. However, despite these extensive and statistically significant 
findings, there is still debate as to how to address this complication once it has been 
 - 12 - Revised 07Dec2009 
identified. 
Wilcox et al3 attempted to investigate the outcome of hematocrit reduction via 
therapeutic phlebotomy and replacement with a dextrose solution. The results point 
to a possibility that GFR could be improved in polycythemic CCHD patients by 
performing this exchange transfusion in effort to reduce hematocrit levels. However, 
this was a very small study (7 patients), and is supported by findings in non-human 
studies.3 Clearly, further investigation needs to be done to determine if elimination of 
erythrocytosis could be safely performed, and if it would be effective in reversing or 
preventing the incidence of cyanotic nephropathy. 
Awad et al4 was also able to investigate possible treatment outcomes by 
studying the effect of palliative surgery on hematocrit levels. Palliative surgery 
resulted in increased oxyhemoglobin saturation, which in turn led to significantly 
decreased hematocrit levels and urine markers for impaired renal function. Palliative 
surgery can decrease the degree of cyanosis, and delay progression to cyanotic 
nephropathy.4 
The implications of elevated hematocrit findings upon medical treatment is 
still yet to be determined. The uncertainty associated with treatment options for 
these patients is only one limitation. The studies included in this systematic review 
have other limitations that should be addressed. For a comprehensive overview of 
criteria for assessing the overall quality of studies included in this systematic review, 
please see Table 1. 
 Variability- There was not substantial variability across studies. The Awad 
et al4 study was published 5 years after the Dittrich et al6 study and cited the Dittrich 
et al study frequently. Both studies also cited many identical resources. Other related 
studies3,7,9 showed similar results, linking elevated hematocrit to the incidence of 
other CCHD related complications (though, these studies were ultimately excluded 
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due to failure to answer the clinical question posed in this systematic review). The 
only exception was Krull et al,8 that reported no statistical correlation between 
proteinuria and hematocrit. However, this study was 25 years old and had a small 
sample size. Moreover, of the small sample size, a very small number of patients 
showed any signs of nephropathy at all. The sample was also a very select group, 
consisting of only patients younger than 25, none of whom had undergone corrective 
surgery.8 This study was ultimately excluded due to the outdated publishing date. 
Therefore, of the two included studies,4,6 there was no variability among results. 
 Other limitations- Both included studies,4,6 being cross-sectional in 
design have an inherent flaw in that they lack longitudinal data. Further studies with 
serial hematocrit measurements over time and the correlation to degree of renal 
impairment would be beneficial. 
 There were also flaws related to sample size. Dittrich et al6 had a sample size 
of only 26 participants, and Awad et al4 had a sample size of 86. The small sample 
size in both studies presented an issue with imprecision. According to Dimopoulos et 
al,10 there is a 9% prevalence of cyanotic nephropathy in patients with CCHD. 
However, according to Dittrich et al,6 38% of their patients showed signs of renal 
impairment. The study conducted by Dittrich et al6 appears to imply that the 
incidence of cyanotic nephropathy is much higher in patients with CCHD than has 
been otherwise observed. This discrepancy may have been eliminated, given a larger 
sample size. 
 Both studies4,6 measured a variety of lab results, one of which was the 
patients’ hematocrit level. The primary focus was not the identification of variability 
of hematocrit. It was not measured in retrospect or an incidental finding, so did not 
pose a serious threat to validity. However, it would have been preferable to see a 
study where hematocrit levels were the primary focus. 
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 Dittrich et al6 had a minor limitation of failure to include a control group. The 
study was not downgraded under this criterion due to the fact that the study 
measured a common laboratory value with previously established, widely accepted 
normal hematocrit ranges. 
 Awad et al4 had more variables that needed refinement. Their sample 
consisted only of children. Given that the incidence of cyanotic nephropathy 
increases with age,4,6 this created an inadequately representative sample. Awad et 
al4 also failed to provide adequate details regarding the timing of when the blood 
sample was taken as compared to the urine sample. If the samples were collected at 
significantly different times, accuracy of the results may have been compromised. 
Despite the limitations of these studies, there is highly suggestive evidence 
that elevated hematocrit is a reliable predictor of cyanotic nephropathy in patients 
with CCHD. A larger study should be performed in order to definitively confirm the 
answer to this question. However, the current evidence is already quite convincing 
and makes physiologic sense. Given these factors, hematocrit evaluation should be a 
routine test in the primary care clinician’s management of patients with CCHD. The 
question of importance of performing hematocrit screening should not be the focus of 
future studies. Future studies should actually focus on frequency of evaluation and 
should establish defined parameters for which urgent referral and treatment should 
be done. Perhaps the most pressing and concerning question is treatment. Further 
studies are severely needed to determine appropriate treatment for these patients. 
CONCLUSION 
While further studies are needed, the lack of variability between current 
studies and statistical significance of measured variables in these studies cannot be 
denied. Further research needs be performed to assess treatment options for these 
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patients, once elevated hematocrit and renal compromise have been identified. 
There is also no research regarding the use of prophylactic renoprotective therapy, 
such as ACE inhibitors, for patients with CCHD. Clearly, the lack of specialty care of 
adult patients with CCHD is a barrier to these studies being conducted. However, one 
barrier that does not need to exist is early identification of cyanotic nephropathy in 
the CCHD patient, as primary care clinicians are able to bridge this gap in patient 
care. 
 One of the challenges that primary care clinicians face is providing continual 
follow-up care for patients with complicated chronic medical illnesses. Without 
specializing in any of these conditions, primary care clinicians need to be able to 
identify risk factors for complications in these patients and refer them on for more 
specialized care. It is vitally important for clinicians to be able to use resources that 
are readily available and affordable to accomplish this. CBC with emphasis on 
hematocrit value is the best resource available to primary care clinicians when 
evaluating patients with CCHD for the risk of developing cyanotic nephropathy. 
Current evidence suggests that frequent hematocrit screening could lead to early 
identification of renal damage, which is reversible in early stages.6 Using hematocrit 
as an evaluation tool, primary care clinicians can positively impact the quality of life 
of patients with CCHD and influence the immediacy of care that these patients 
receive from specialists. 
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
Dittrich et al Cross-sectional Not Serious Not Serious Not Serious Seriousa Unlikely None Very Low 
Awad et al Cross-sectional Not Serious Not Serious Not Serious Seriousa Unlikely None Very Low 
a Small sample size 
 
 
 
 
